Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 SEP 21 ... researchers in the United States conducted a study "To define the optimal dose of Polyphenon E for chronic daily administration and tolerability in patients with chronic lymphocytic ...
2009 JUN 8 ... first clinical trial, 33 patients received variations of eight different oral doses of Polyphenon E, a proprietary compound whose primary active ingredient is EGCG. Doses ranged from 400 ...
2009 JUL 6 ... cancer progression. "The investigational agent used in the trial, Polyphenon E (provided by Polyphenon Pharma) may have the potential to lower the incidence and slow ...
2009 AUG 31 ... aim of this study was to evaluate the chemopreventive effects of black tea polyphenols (Polyphenon-B) on markers of invasion and angiogenesis during dimethylaminoazobenzene (DAB)-induced ...
2009 JUL 20 ... lung tumorigenesis in mice by aerosol administration." "In this study, Polyphenon E and Polyphenon E without EGCG were administered by ...
2009 NOV 2 ... the molecular mechanisms are not well defined. We demonstrate that administration of Polyphenon E (Poly E), a standardized green tea extract, inhibited MDA-MB231 breast cancer and human ...
2009 AUG 24 ... prostate biopsies and scheduled for radical prostatectomy were given daily doses of Polyphenon E, which contained 800 mg of (-)-epigallocatechin-3-gallate (EGCG) and lesser amounts of ...
2008 SEP 1 ... flavan-3-ols in the small intestine, human subjects with an ileostomy ingested 200 mg of Polyphenon E, a green tea extract, after which ileal fluid and urine, collected over a 24-h period, ...
2008 AUG 11 ... and Drug Administration (FDA) has granted Orphan Drug Designation to its botanical drug, Polyphenon E(R), for the treatment of chronic lymphocytic leukemia (CLL). A Phase II study is ...
2008 AUG 18 ... study investigated the possible synergistic inhibitory effect of a novel combination of polyphenon E (PPE, a standardized green tea polyphenol preparation) and atorvastatin (trade name ...
2008 JUN 30 ... exert antiviral, antioxidative, antiproliferative and immunostimulatory activity. Polyphenon(R) E (MediGene AG, Munich, Germany), a proprietary extract of green tea leaves, was ...
2008 SEP 22 ... "Therefore, we examined whether long-term administration of green tea catechins [Polyphenon E (PE): 63% of epigallocatechin-3-gallate, 11% of epicatechin, 6% of (-)-epigallocatechin ...
2008 SEP 1 ... antioxidant capabilities (and putative mechanisms of action) of green tea extract (GTE), polyphenon-60 (PP-60, 60% pure polyphenols), (-)-epicatechin-3-gallate (ECG) and ...
2008 OCT 27 ... safety profile. Here, we describe the use of the decaffeinated green tea extract Polyphenon E (Poly E) (1% in diet) and aerosolized difluoromethylornithine (DFMO) (20 mg/kg/day, 5 ...
